Gelteq Limited
$0.7
▼
-8.04%
2026-04-21 07:02:02
www.gelteq.com
NCM: GELS
Explore Gelteq Limited stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$7.5 M
Current Price
$0.7
52W High / Low
$4.11 / $0.64
Stock P/E
—
Book Value
$1.09
Dividend Yield
—
ROCE
-31.25%
ROE
-42.99%
Face Value
—
EPS
$-0.51
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
7
Beta
—
Debt / Equity
26.68
Current Ratio
0.27
Quick Ratio
0.27
Forward P/E
—
Price / Sales
18.04
Enterprise Value
$11.33 M
EV / EBITDA
-2.95
EV / Revenue
27.42
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | SCYNEXIS, Inc. | $1.07 | — | $47.85 M | — | -30.16% | -16.48% | $1.31 / $0.56 | $1.13 |
| 2. | Ironwood Pharmaceuticals, Inc. | $4.42 | 29.94 | $719.09 M | — | 76.78% | -8.53% | $5.78 / $0.53 | $-1.61 |
| 3. | Eton Pharmaceuticals, Inc. | $25.28 | — | $683.2 M | — | -1.57% | -18.19% | $27.29 / $13.09 | $0.97 |
| 4. | Citius Oncology, Inc. | $0.92 | — | $77.5 M | — | -45.72% | -47.41% | $6.19 / $0.49 | $0.69 |
| 5. | Dr. Reddy's Laboratories Limited | $12.97 | 17.86 | $11.1 B | 0.65% | 19.86% | 16.1% | $1,379.7 / $1,129 | $4.78 |
| 6. | Viatris Inc. | $14.78 | — | $17.2 B | 3.23% | 0.84% | -21.08% | $16.47 / $7.39 | $12.78 |
| 7. | Elanco Animal Health Incorporated | $22.34 | — | $11.2 B | — | 2.14% | -3.67% | $27.72 / $8.02 | $13.17 |
Quarterly Results
Figures shown in M / B
| Sales |
|---|
| Operating Profit |
| Net Profit |
| EPS in Rs |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.17 M | 0 M | 0.08 M | 0.15 M |
| Operating Profit | -4.95 M | -2.61 M | -3.38 M | -3.19 M |
| Net Profit | -6.65 M | -3.55 M | -3.51 M | -3.37 M |
| EPS in Rs | -0.62 | -0.33 | -0.33 | -0.31 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 21.48 M | 20.76 M | 22.49 M | 23.41 M |
| Total Liabilities | 5.67 M | 5.65 M | 3.84 M | 2.55 M |
| Equity | 15.8 M | 15.11 M | 18.66 M | 20.86 M |
| Current Assets | 1.51 M | 0.3 M | 0.99 M | 0.72 M |
| Current Liabilities | 5.63 M | 3.87 M | 1.36 M | 1.08 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | — | — | — | — |
| Investing CF | -0.74 M | -0.15 M | -0.08 M | 0 M |
| Financing CF | 6.45 M | 0.84 M | 2.03 M | 1.49 M |
| Free CF | -6.16 M | -1.22 M | -1.85 M | -1.51 M |
| Capex | -0.64 M | -0.15 M | -0.08 M | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | -45.88% | — | — |
| Earnings Growth % | -1.14% | -4.08% | — | — |
| Profit Margin % | — | -4391.39% | -2283.44% | — |
| Operating Margin % | — | -4232.88% | -2165.08% | — |
| Gross Margin % | — | 38.72% | 35.69% | — |
| EBITDA Margin % | — | -2349.87% | -1341.45% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.